Logo Università degli Studi di Milano



 
 

Team - Laboratory of Cellular Pharmacology of Atherosclerosis  

dott Arnaboldi

Lorenzo Arnaboldi

E-mail: Lorenzo.arnaboldi@unimi.it

Phone +39 02 50318321

Degree in Pharmacy, PhD in Experimental Pharmacology, PhD in Pharmacology/Biotechonologies (UNIMI); 3-years Post-Doc Fellow at the Gladstone Institutes, UCSF, USA; Author of 29 papers on peer-reviewed journals   

Expertise
-Role of lipid/lipoprotein/vesicles in atherosclerosis, metabolic syndrome, Alzheimer’s Disease, retinopathies, tumors, frail elderly and their pharmacological modulation.
-Antiproliferative molecules

 

drssa Castiglioni

 

Silvia Castiglioni

E-mail: silvia.castiglioni@unimi.it

Phone +39 02 50318346

Degree in Pharmacy, University of Milan; PhD in Drug Metabolism and Pharmacokinetics, University of Bari.

Expertise: cigarette smoke and atherogenesis, smooth muscle cells phenotypic switch during atherogenesis. 

Scientific secretary of the Master in Oncological Pharmacy and Pharmacology and of the advanced course in Oncological Pharmacy.
Co-Author of 10 publications on peer-reviewed scientific journals.


dr Accattatis


Felice Maria Accattatis

E-mail: felice.accattatis@unimi.it

Phone +39 02 50318346

Expertise:- Cell culture. Characterization of Extracellular vesicles’ lipid and protein profiles to unravel their role in pathophysiological processes, pharmacological modulation
- Antiproliferative and cholesterol-lowering drugs.

Degree in Pharmaceutical Chemistry and Technology (Università degli Studi della Calabria), Master in Oncological Pharmacy and Pharmacology (UNIMI).

 

drssa Damiani

 

Isabella Damiani

E-mail: isabella.damiani@unimi.it

Phone +39 02 50318346

Degree in Pharmaceutical Biotechnology, University of Milan.

Erasmus scholarship at University of Wroclaw-Poland; 

“Promising Young Researchers” scholarship at University of Milan

Research fields: cigarette smoke and atherogenesis, epigenetic modulation in smooth muscle cells phenotypic switch during atherogenesis, HER2 receptor modulation in breast cancer.

Back to top